Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: Results from the DIASPORA study

Diabetes and Vascular Disease Research

Volumn 7, Issue 2, 2010, Pages 145-150

  Schöndorf, Thomas ^a,b,c   Lübben, Georg ^d   Karagiannis, Efstrathios ^d   Erdmann, Erland ^b   Forst, Thomas ^a   Pfützner, Andreas ^a,c  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c University of Applied Science   (Germany)

^d Takeda Pharma GmbH   (Germany)

Author keywords

Angiodiabetes; Biomarker profile; Cardiodiabetes; Cardiovascular risk

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DISEASE MARKER; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; CARDIOLOGY; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; GLUCOSE TOLERANCE TEST; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

AGED; CARDIOLOGY; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 77954463628     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109358241     Document Type: Article

References (25)

1. Martin S, Schramm W, Schneider B, et al. (2007) Epidemiology of complications and total treatment costs from diagnosis of type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 115: 495-501.
2. Mainous AG III, Baker B, Koopman RJ, et al. (2007) Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia 50: 934-10.
3. Bartnik M, Norhammar A, Rydén L (2007) Hyperglycaemia and cardiovascular disease. J Intern Med 262: 145-56.
4. Norhammar A, Lindbäck J, Rydén L, Wallentin L, Stenestrand U (2007) Improved but still high short and long-term mortality after myocardial infarction in patients with diabetes mel- litus. A time trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart; 93: 1577-83.
5. Bartnik M, Rydén L, Ferrari R, et al. (2004) Abnormal glucose regulation in patients with coronary artery disease across Europe. Diabetologia 47(suppl. 1): A61.
6. Lauruschkat AH, Anrich B, Albert AA, et al. (2005) Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. Circulation 112: 2397-402.
7. Rathmann W, Haastert B, Icks A, et al. (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000. Diabetologia 46: 182-9.
8. Rathmann W, Icks A, Haastert B, Giani G, Löwel H, Mielck A (2002) Undiagnosed diabetes mellitus among patients with prior myocardial infarction. Z Kardiol 91: 620-5.
9. Aronson D, Rayfield EJ, Chesebro JH (1997) Mechanism determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 126: 296-306.
10. Taubert G, Winkelmann BR, Schleiffer T, et al. (2003) Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 145: 285-91.
11. Rydén L, Standl E, Bartnik M, et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136.
12. Hauner H, Hanisch J, Bramlage P, et al. (2008) Prevalence of undiagnosed type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and cardiovascular Risk Project (GEMCAS). Exp Clin Endocrinol Diabetes; 116: 18-25.
13. Erdmann E (2005) Diabetes and cardiovascular risk markers. Curr Med Res Opin 21(Suppl 1): S21-8.
14. Lenzen M, Rydén L, Ohrvik J, et al. (2006) Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 27: 2969-74.
15. Liu J, Grundy SM, Wang W, et al. (2007) Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 153: 552-8.
16. Pankow JS, Kwan DK, Duncan BB, et al. (2007) Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 30: 325-7.
17. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA, dekker JM (2007) High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 30: 332-6.
18. Twigg SM, Kamp MC, Davis TM, Neyion EK, Flack JR, Australian Diabetes Society, Australian Diabetes Educators Association (2007) Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 186: 461-5.
19. PfÜtzner A, Kunt T, Mondok A, et al. (2004) Fasting intact pro insulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27: 682-7.
20. Leonhardt W, Pfützner A, Müller I, et al. (2008) Effects of pioglitazone and/or simvastatin on low density lipoprotein sub fractions in non-diabetic patients with high cardiovascular risk: a sub-analysis from the PIOSTAT study. Atherosclerosis 201: 155-62.
21. Forst T, Pfützner A, Lübben G, et al. (2007) Effect of simvastatin and/or piogliazone on insulin resistance, insulin secretion, adi- ponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism 56: 491-6.
22. Hanefeld M, Marx N, Pfützner A, et al. (2007) Antiinflammatory effect of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitive CRP: the PIOSTAT study. J Am Coll Cardiol 49: 291-8.
23. Thrainsdottir IS, Aspelund T, Hardarson T, et al. (2005) Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. Eur J Cardiovasc Prev Rehabil 12: 465-71.
24. Wallander M, Bartnik M, Efendic S, et al. (2005) Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia 48: 2229-35.
25. Tamita K, Katayama M, Takagi T, et al. (2007) Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J 71: 834-41.